Merck KGaA’s Erbitux Fails in Colon Cancer Study

Germany's Merck KGaA said on Wednesday that Erbitux, one of its most important drugs, failed to help colon cancer patients after surgery in a late stage trial. A scheduled interim analysis of the so-c…
Read the full story: BioSpace.com Featured News